APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line.

We have found a novel alternative splicing product of the apoptotic protease activating factor 1 (APAF-1), termed APAF-1-ALT, in the LNCaP human prostate cancer cell line. APAF-1-ALT harbors the caspase recruitment domain and an incomplete CED-4 like/ATPase domain, but lacks the WD-40 repeat units. The LNCaP cell expressed the full-length APAF-1 weakly and APAF-1-ALT rather abundantly, especially after mycoplasma infection. LNCaP underwent a retarded DNA damage-induced apoptosis, which was independent of caspase 9 activity. APAF-1-ALT functioned less effectively in inducing apoptosis than did APAF-1-XL, the full-length APAF-1, in transient transfection. Moreover, APAF-1-ALT interfered with APAF-1-XL's ability to induce apoptosis in transient double transfection experiment. These results indicate that APAF-1-ALT is a molecule that is deficient and impeded for mediating apoptosis and that it may contribute to the resistance to DNA damage-induced treatment observed in LNCaP.

[1]  Xiaodong Wang,et al.  Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. , 2002, Cancer research.

[2]  A. Horii,et al.  The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. , 1999, Journal of biochemistry.

[3]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[4]  X. Liu,et al.  An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9* , 1999, The Journal of Biological Chemistry.

[5]  Shien Tsai,et al.  Mycoplasmal Infections Prevent Apoptosis and Induce Malignant Transformation of Interleukin-3-Dependent 32D Hematopoietic Cells , 1999, Molecular and Cellular Biology.

[6]  J. Shih,et al.  Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Núñez,et al.  Expression and Functional Analysis of Apaf-1 Isoforms , 2000, The Journal of Biological Chemistry.

[8]  Yigong Shi,et al.  Oligomerization and activation of caspase-9, induced by Apaf-1 CARD , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Shou,et al.  Mycoplasma infections and different human carcinomas. , 2001, World journal of gastroenterology.

[10]  K. Helin,et al.  Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.

[11]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[12]  A. Horii,et al.  Alternative splicing of hMSH2 in normal human tissues , 1997, Human Genetics.

[13]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[14]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[15]  T. Mak,et al.  Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.

[16]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[17]  A. Horii,et al.  Frequent loss of copy number on the long arm of chromosome 21 in human esophageal squamous cell carcinoma. , 2000, International journal of oncology.